An eye on glaucoma drugs

Two recent drugs have opened new treatment opportunities for this common eye disease.

Glaucoma is a leading cause of blindness in people over age 60, and it’s estimated that the number of new cases will more than double over the next few decades. “There is no cure for glaucoma once it appears, so treating it at its earliest stages can help save your vision,” says Dr. David Solá-Del Valle, an ophthalmologist with Harvard-affiliated Massachusetts Eye and Ear.
Once diagnosed, glaucoma is treated with eye drops to reduce pressure inside the eye by lowering the amount of fluid or improving fluid drainage. They can keep glaucoma from getting worse and hopefully avoid the need for surgery to correct this drainage problem.
Now, two new eye drops that have recently emerged on the market could assist people who need extra help the current medications can’t offer. “These are a welcome addition, as there haven’t been any new and more effective glaucoma drugs developed in many years,” says Dr. Solá-Del Valle.
Glaucoma is a condition of elevated pressure within the eye that can damage the optic nerve, potentially leading to vision loss and blindness.  There are many types of glaucoma, but the most common is open-angle glaucoma, which occurs when the eye does not drain fluids well. Eventually, pressure from the backed-up fluids builds up and damages the optic nerve. (This is the kind that is generally referred to as simply “glaucoma.”
Four common classes of eye drops, along with various combinations, are used to treat glaucoma (see “Types of glaucoma eye drops”). The two new drugs are netarsudil (Rhopressa) and latanoprostene bunod (Vyzulta)……
Read more: https://www.health.harvard.edu/newsletter_article/an-eye-on-glaucoma-drugs
Source: Health Harvard

On